SightfileU.S. market data from official filings

ANNOVIS BIO INC (ANVS)

Name: ANNOVIS BIO INC (ANVS) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001477845 · EDGAR filings · Updated 2026-07-10

ANNOVIS BIO INC (ANVS) has reported institutional ownership of 16.7%, with 56 institutional managers holding positions valued at $10.5M per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Institutional ownership

16.7%

Institutional managers

Reported 13F value

$10.5M

Insider activity

29 trans.

$2.82M net buying

Data flags

3 active

from SEC filings

Latest updates

2026-07-10 — Current report (8-K) filed
2026-06-17 — Current report (8-K) filed
2026-05-21 — Insider transaction reported (Form 4)
2026-05-20 — Current report (8-K) filed
2026-05-20 — Prospectus supplement (424B5) filed
2026-05-19 — Prospectus supplement (424B5) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ANNOVIS BIO INC has 56 institutional holders and institutional ownership of 16.7%.

Insider activity

Insiders reported 29 transactions (15 buys, 0 sells) across 5 reporting insiders, with a net reported value of $2.82M.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-15 (recurring since 2020-03-25) — source filing. The authoritative details are those stated in the filing itself.

Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2025-03-27 (recurring since 2021-11-15) — source filing. The authoritative details are those stated in the filing itself.

Active non-reliance notice on previously issued financial statements (8-K Item 4.02), most recently filed 2023-03-06 (recurring since 2023-03-06) — source filing. The authoritative details are those stated in the filing itself.

Related companies

Clene Inc (CLNN) · Aytu BioPharma Inc (AYTU) · ORGANIGRAM GLOBAL INC (OGI) · SAFE PRO GROUP INC (SPAI) · OKYO PHARMA LTD (OKYO) · SKYE BIOSCIENCE INC (SKYE)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-10.